MiRNA-based anticancer therapy: Tumor suppressor MiRNA-218 suppresses the expression L1CAM via down regulation of their target genes, 15/February/20145, 22.04

Small molecule-based therapy for Visceral pain: TWIST1 decreases visceral pain in patients with Irritable Bowel Syndrome via up regulation of its target gene, 15/February/2015, 21.27
February 15, 2015
Molecular mechanisms of tumorigenesis: Neurotensin increases the expression of oncogenic protein MDM2, a negative regulator of tumor suppressor p53, via up regulation of its target gene, 15/February/2015, 22.34
February 15, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, MiRNA-based anticancer therapy: Tumor suppressor MiRNA-218 suppresses the expression L1CAM via down regulation of their target genes, 15/February/20145, 22.04, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: This study suggests, for the first time, that tumor suppressor MiRNAs-218, by decreasing the expression of  their target gene, it may inhibit the expression of L1CAM. Thereby, it may inhibit the migration and invasion of cancer cells. Thus, pharmacological formulations encompassing “MiRNA-218 activators”  can be used to inhibit metastatic human tumors

Amount: $ 300*

Undisclosed information: How MiRNA-218 suppresses the expression of L1CAM.

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.